Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis

Systemic Lupus Erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

J Rheumatol

Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH

doi: 10.3899/jrheum.200802

Systemic Lupus Erythematosus

Mortality among Hospitalized Individuals with Systemic Lupus Erythematosus in the United States between 2006 and 2016

Arthritis Care Res (Hoboken).

Anastasiou C, Trupin L, Glidden DV, Li J, Gianfrancesco M, Shiboski S, Schmajuk G, Yazdany J

doi: 10.1002/acr.24356.

Systemic Lupus Erythematosus

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Clin Neurol Neurosurg.

Carnero Contentti E, Genco ND, Hryb JP, Caspi M, Chiganer E, Di Pace JL, López PA, Lessa C, Caride A, Perassolo M

doi: 10.1016/

Systemic Lupus Erythematosus

Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients with Systemic Lupus Erythematosus

Arthritis Rheumatol.

Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM, NYU WARCOV Investigators.

doi: 10.1002/art.41450.

Systemic Lupus Erythematosus

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program

Arthritis Care Res (Hoboken).

Charoenwoodhipong P, Harlow SD, Marder W, Hassett AL, McCune WJ, Gordon C, Helmick CG, Barbour KE, Wang L, Mancuso P, Somers EC, Zick SM

doi: 10.1002/acr.23925.

Systemic Lupus Erythematosus

A Population-based Study of Perinatal Infection Risk in Women with and without Systemic Lupus Erythematosus and their Infants

Paediatr Perinat Epidemiol.

Bender Ignacio RA, Madison AT, Moshiri A, Weiss NS, Mueller BA

doi: 10.1111/ppe.12430.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

doi: 10.1136/annrheumdis-2018-214427.

Systemic Lupus Erythematosus

Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland

Swiss Med Wkly.

von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, Schaer DJ, Mueller RB

doi: 10.4414/smw.2019.20022.

Systemic Lupus Erythematosus

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

Ann Rheum Dis.

Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V

doi: 10.1136/annrheumdis-2019-216150.

Related content

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

Mortality among Hospitalized Individuals with Systemic Lupus Erythematosus in the United States between 2006 and 2016

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients with Systemic Lupus Erythematosus

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program

A Population-based Study of Perinatal Infection Risk in Women with and without Systemic Lupus Erythematosus and their Infants

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach